Talacotuzumab 塔妥珠单抗; JNJ 56022473; CSL 362|cas:1826831-79-1|西域试剂

Talacotuzumab 塔妥珠单抗; JNJ 56022473; CSL 362,95.0%

产品编号：Bellancom-P99395| CAS NO：1826831-79-1

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99395		￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Talacotuzumab 塔妥珠单抗; JNJ 56022473; CSL 362

产品介绍

Talacotuzumab (JNJ 56022473; CSL 362) 是一种 IgG1 型完全人源化的 CD123 中和单克隆抗体，含有修饰的 Fc 结构。Talacotuzumab 对 CD123、CD32b/c、CD16-158F、CD16-158V 的 K_D 分别为 0.43 nM、188 nM、46 nM、16.8 nM。Talacotuzumab 抑制 IL-3 与 CD123 的结合，从而拮抗靶细胞中的 IL-3 信号传导。Talacotuzumab 使 Fc 区发生突变以增加对 CD16 (FcγRIIIa) 的亲和力，从而增强抗体依赖性细胞介导的细胞毒性 (ADCC)。Talacotuzumab 在体内非常有效地减少急性髓性白血病 (AML) 异种移植小鼠模型中的白血病细胞生长。

生物活性

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models^[4].

体外研究

塔妥珠单抗 (JNJ 56022473; CSL 362) 强烈介导 TF-1 细胞的抗体依赖性细胞介导的细胞毒性 (ADCC)，IC₅₀ 为 5 ng/ml (33 pM)。
塔妥珠单抗 (1 μg/ml; 预处理 24 小时) 抑制 SLE 供体和健康供体浆细胞样树突状细胞和嗜碱性粒细胞中 TLR7 刺激 (咪喹莫特; HY-B0180; 0.5 μM; 6 天) 和 TLR9 刺激 (CpG C; 0.5 μM; 6 天) IFN-α 的产生，而 TLR4 刺激 (LPS; HY-D1056; 10 μg/ml) IFN-α 的产生没有显着减少。塔妥珠单抗通过耗尽浆细胞样树突状细胞 (pDC) 来抑制 TLR7 和 TLR9 诱导的浆母细胞扩增和增殖

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

塔妥珠单抗 (JNJ 56022473; CSL 362; 300 μg; 腹腔注射; 每周三次持续 5 周) 与同种型对照相比，在急性髓性白血病小鼠异种移植物中导致肿瘤生长显着延迟。
塔妥珠单抗 (1, 10, 30 mg/kg; 皮下注射; 单次注射) 在幼稚食蟹猴中以 1、10、30 mg/kg 的剂量在 48 小时最大血清浓度分别为 12、190 和 380 μg/ml。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nonobese diabetic/severe combined immunodeficiency mice injected intravenously AML xenograft cells (AML-5)
Dosage:	300 μg
Administration:	IP; thrice weekly for 5 weeks
Result:	Resulted in a significant delay in tumor growth compared with an isotype control.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nonobese diabetic/severe combined immunodeficiency mice injected intravenously AML xenograft cells (AML-5)
Dosage:	300 μg
Administration:	IP; thrice weekly for 5 weeks
Result:	Resulted in a significant delay in tumor growth compared with an isotype control.